和記黃埔

China is proving a tonic for investors

It is not the small brown pills that stand out at the Shanghai No. 1 TCM factory, produced by shiny machines inside pressure-controlled rooms and supervised by technicians in white coats. It is the ingredients.

Like any western drugmaker, Shanghai Hutchison Pharmaceuticals, the joint owner, produces neatly printed packets of medicine to high-quality standards, complete with holograms to dissuade counterfeiters. But the contents include musk, mandarin orange peel and cow’s liver.

SHPL, part of Hutchison Whampoa, one of Hong Kong’s most powerful conglomerates, is capitalising on surging demand for traditional Chinese medicine (TCM), which is attracting businesses and investors domestically and abroad.

您已閱讀15%(706字),剩餘85%(4097字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×